Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

The approval makes ILM-Blue the first DORC posterior dye product available in China, according to a press release from Zeiss.

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

Urcosimod (formerly known as OK-101) has been shown to be stable for over 2 and a half years in single-use ampoules used for administration of the drug to patients.